1. Home
  2. WEYS vs MNPR Comparison

WEYS vs MNPR Comparison

Compare WEYS & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weyco Group Inc.

WEYS

Weyco Group Inc.

HOLD

Current Price

$34.54

Market Cap

331.9M

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$62.46

Market Cap

368.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEYS
MNPR
Founded
1906
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
331.9M
368.9M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
WEYS
MNPR
Price
$34.54
$62.46
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$107.00
AVG Volume (30 Days)
12.0K
164.9K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
3.24%
N/A
EPS Growth
N/A
54.99
EPS
0.64
N/A
Revenue
$276,169,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$54.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.25
$28.40
52 Week High
$35.69
$105.00

Technical Indicators

Market Signals
Indicator
WEYS
MNPR
Relative Strength Index (RSI) 55.13 57.35
Support Level $30.62 $51.71
Resistance Level N/A $67.90
Average True Range (ATR) 1.38 5.62
MACD 0.10 0.25
Stochastic Oscillator 75.59 69.41

Price Performance

Historical Comparison
WEYS
MNPR

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, South Africa, and Australia.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: